Compare Alexandria Real Estate Equities Inc (ARE) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alexandria Real Estate Equities Inc vs Neurocrine Biosciences Inc — how do they compare? Alexandria Real Estate Equities Inc trades at $48.5 (market cap $8.28B), while Neurocrine Biosciences Inc trades at $156 (market cap $16.46B). The key difference: Neurocrine Biosciences Inc is the larger of the two by market cap, and Alexandria Real Estate Equities Inc pays a 5.99% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| ARE | NBIX | |
|---|---|---|
Market Cap | $8.28B | $16.46B |
Sector | Real Estate | Health |
52-Week High | $87.45 | $185.50 |
52-Week Low | $40.41 | $123.10 |
Enterprise Value | $20.98B | $16.48B |
Dividend Yield | 5.99% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alexandria Real Estate Equities Inc
Alexandria Real Estate Equities Inc is an urban office real estate investment trust (REIT). It is engaged in the business of providing space for lease to life science, agtech, and technology tenants. The company has established a significant market presence in key locations, including Greater Boston, the San Francisco Bay Area, New York City, San Diego, Seattle, Maryland, and Research Triangle. Alexandria has a longstanding and proven track record of developing Class A properties clustered in urban life science, agtech, and technology campuses that provide tenants with highly dynamic and collaborative environments. Alexandria also provides strategic capital to transformative life science, agtech, and technology companies through venture capital platform.
Read more on ARE →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
